Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in King of Prussia, PA, US. The stock last traded at $1.08, down 0.46% on the session, giving a market capitalisation of $12.6M. On trailing twelve-month figures it carries a trailing P/E of -0.81, a net margin of 0.0%. Its beta of 0.79 implies it has historically moved less than the broad market.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Phio Pharmaceuticals Corp. is most often compared with the following Healthcare names: